10x Genomics
10x Genomics' revenue rose 5.2% to $643 million in fiscal 2025. Its operating margin was −9.5%, up from −31.9% a year earlier. Free cash flow was $130 million. The diluted share count rose 3.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What 10x Genomics does
This company sells instruments, chemical consumables and software that let scientists study biology one cell at a time and see where molecules sit inside tissue. Its customers are researchers at universities, medical research centers and drug companies. The company says its products have been used in more than 10,000 peer-reviewed articles.
It has two main product families. Its single cell portfolio, built on the Chromium platform, splits samples into tiny partitions, tags each with a barcode, and then reads them together on a sequencer, so researchers can measure many cells in parallel. Its spatial portfolio, built on the Visium and Xenium platforms, maps where biological molecules are in a tissue sample. It earns money from selling instruments and from the chips, reagents and other consumables customers must buy to run them.
Revenue was $642.8 million in 2025, up 5% from the year before. It reported a net loss in 2025 and in 2024.
Its biggest risks, as it describes them
- Its quarterly and yearly results can swing widely and are hard to predict.
- It faces intense competition, including rivals developing new technologies that could replace its products.
- Price cuts or discounts could hurt its results if it does not gain offsetting benefits.
- It may fail to develop new products or improved versions of existing ones.
- Its demand depends on research spending by institutions, and a reduction would limit sales.
Income statement
10x Genomics lost money in fiscal 2025: a net loss of $44 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 587 | 430 | 389 | 393 | 523 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −587 | −430 | −389 | −393 | −523 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −60.3x | −352.8x | −8,040.3x | −48,639.8x | — |
| Current ratio | 6.8x | 4.8x | 4.7x | 5.0x | 4.5x |
| Quick ratio | 6.2x | 4.2x | 4.1x | 4.3x | 4.1x |
Cash flow
Projections
Project 10x Genomics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought 10x Genomics shares on the open market, and 6 insiders sold $18.8 million, $9.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Serge SaxonovChief Executive Officer, Director | Sold | 31,000 | $62.90 | $1.9 million | Form 4 |
| Sep 22, 2026 | Serge SaxonovChief Executive Officer, Director | Sold plan | 25,000 | $81.22 | $2.0 million | Form 4 |
| Sep 22, 2026 | Shehnaaz SulimanDirector | Sold plan | 5,723 | $81.19 | $464,677 | Form 4 |
| Sep 9, 2026 | Adam TaichChief Financial Officer | Sold plan | 46,388 | $64.58 | $3.0 million | Form 4 |
| Sep 3, 2026 | John R StuelpnagelDirector | Sold | 20,000 | $61.76 | $1.2 million | Form 4 |
| Aug 26, 2026 | Serge SaxonovChief Executive Officer, Director | Sold plan | 10,486 | $63.70 | $667,913 | Form 4 |
| Aug 24, 2026 | Serge SaxonovChief Executive Officer, Director | Sold | 18,545 | $63.02 | $1.2 million | Form 4 |
| Aug 24, 2026 | Adam TaichChief Financial Officer | Sold | 17,166 | $63.02 | $1.1 million | Form 4 |
| Aug 24, 2026 | Benjamin J. HindsonSee Remarks, Director | Sold | 13,818 | $63.02 | $870,810 | Form 4 |
| Aug 24, 2026 | Shehnaaz SulimanDirector | Sold plan | 2,207 | $63.65 | $140,486 | Form 4 |
| Aug 14, 2026 | Sarah A. TeichmannDirector | Sold plan | 2,273 | $57.15 | $129,902 | Form 4 |
| Aug 13, 2026 | Sarah A. TeichmannDirector | Sold plan | 5,278 | $57.29 | $302,377 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 6 of 9 | 5 of 9 |
| Rule of 40 | 9.5% | −2.2% | 25.5% |
| Altman Z'' | 0.47 | 0.28 | 1.63 |
| Accruals ratio | −24.1% | −20.1% | −18.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 2 of 9 | 6 of 9 | 5 of 9 |
Compare
Put 10x Genomics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| 10x Genomics | FY25 | 5.2% | −9.5% | 20.2% | −16.3% | — | 5 | |
| Azenta | FY25 | 3.5% | −4.5% | 6.5% | — | — | — | Compare |
| Bio-Techne | FY26 | −0.4% | 20.7% | 21.7% | 9.2% | −0.2x | 9 | Compare |
| Mesa Laboratories | FY26 | 3.4% | 7.4% | 15.9% | 4.8% | 1.0x | 8 | Compare |
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 71 | 146 | 246 | 299 | 490 | 516 | 619 | 611 | 643 |
| Revenue growth | — | 105.8% | 68.1% | 21.5% | 64.1% | 5.3% | 19.8% | −1.3% | 5.2% |
| Gross profit | 60 | 118 | 185 | 240 | 416 | 396 | 409 | 414 | 444 |
| Research and development | 32 | 48 | 83 | 123 | 212 | 266 | 270 | 265 | 239 |
| Operating income | −18 | −111 | −31 | −534 | −52 | −168 | −265 | −195 | −61 |
| Net income | −19 | −112 | −31 | −543 | −58 | −166 | −255 | −183 | −44 |
| Diluted EPS (US$) | −1.62 | −8.40 | −0.80 | −5.37 | −0.53 | −1.46 | −2.18 | −1.52 | −0.35 |
| Diluted shares (millions) | 12 | 13 | 39 | 101 | 110 | 114 | 117 | 120 | 125 |
| Cash flow | |||||||||
| Cash from operations | −11 | −76 | 35 | −218 | −21 | −34 | −15 | 7 | 136 |
| Capital expenditure | 4 | 6 | 43 | 37 | 101 | 132 | 49 | 12 | 6 |
| Free cash flow | −14 | −83 | −8 | −255 | −123 | −165 | −64 | −6 | 130 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 6 | 4 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 3 | 13 | 49 | 96 | 137 | 167 | 141 | 109 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 48 | 65 | 424 | 664 | 587 | 430 | 389 | 393 | 523 |
| Debt incl. finance leases | — | 30 | 30 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | — | 124 | 606 | 929 | 1,019 | 1,029 | 965 | 919 | 1,041 |
| Total liabilities | — | 101 | 186 | 190 | 201 | 223 | 224 | 208 | 245 |
| Shareholders' equity | −112 | −220 | 420 | 739 | 818 | 806 | 741 | 710 | 796 |
| Margins and ratios | |||||||||
| Gross margin | 85.1% | 80.4% | 75.2% | 80.4% | 84.9% | 76.7% | 66.2% | 67.9% | 69.0% |
| Operating margin | −25.9% | −75.7% | −12.4% | −178.7% | −10.7% | −32.5% | −42.9% | −31.9% | −9.5% |
| Net margin | −26.4% | −76.9% | −12.7% | −181.6% | −11.9% | −32.1% | −41.2% | −29.9% | −6.8% |
| Free cash flow margin | −20.3% | −56.5% | −3.3% | −85.2% | −25.0% | −32.0% | −10.3% | −0.9% | 20.2% |
| Rule of 40 (growth + FCF margin) | — | 49.3% | 64.8% | −63.6% | 39.1% | −26.7% | 9.5% | −2.2% | 25.5% |
| Return on capital | — | — | — | — | −27.0% | −43.8% | −57.6% | −45.9% | −16.3% |
| Return on equity | — | — | −31.2% | −93.6% | −7.5% | −20.4% | −33.0% | −25.2% | −5.8% |
| Return on assets | — | — | −8.6% | −70.7% | −6.0% | −16.2% | −25.6% | −19.4% | −4.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |